180 related articles for article (PubMed ID: 22205840)
1. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Chang HJ; Lee JH; Do YR; Bae SH; Lee JL; Nam SH; Yoon SS; Bang SM
Korean J Intern Med; 2011 Dec; 26(4):403-9. PubMed ID: 22205840
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
4. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
6. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Lu J; Lee JH; Huang SY; Qiu L; Lee JJ; Liu T; Yoon SS; Kim K; Shen ZX; Eom HS; Chen WM; Min CK; Kim HJ; Lee JO; Kwak JY; Yiu W; Chen G; Ervin-Haynes A; Hulin C; Facon T
Br J Haematol; 2017 Mar; 176(5):743-749. PubMed ID: 28106903
[TBL] [Abstract][Full Text] [Related]
7. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
8. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
9. Is the low-thalidomide dose MPT regimen beneficial?
Min CK
Korean J Intern Med; 2011 Dec; 26(4):400-2. PubMed ID: 22205839
[No Abstract] [Full Text] [Related]
10. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Palumbo A; Davies F; Kropff M; Bladé J; Delforge M; Leal da Costa F; Garcia Sanz R; Schey S; Facon T; Morgan G; Moreau P
Ann Hematol; 2010 Aug; 89(8):803-11. PubMed ID: 20232066
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
12. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
[TBL] [Abstract][Full Text] [Related]
13. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
14. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
15. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Sacchi S; Marcheselli R; Lazzaro A; Morabito F; Fragasso A; Di Renzo N; Balleari E; Neri S; Quarta G; Ferrara R; Vigliotti ML; Polimeno G; Musto P; Consoli U; Zoboli A; Buda G; Pastorini A; Masini L
Leuk Lymphoma; 2011 Oct; 52(10):1942-8. PubMed ID: 21663513
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myeloma: recent developments.
Zweegman S; Huijgens PC
Anticancer Drugs; 2002 Apr; 13(4):339-51. PubMed ID: 11984079
[TBL] [Abstract][Full Text] [Related]
19. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
20. The importance of complete response in outcomes in myeloma.
Nooka A; Kaufman J; Lonial S
Cancer J; 2009; 15(6):465-72. PubMed ID: 20010165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
